{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T06:12:58Z","timestamp":1782886378108,"version":"3.54.5"},"reference-count":137,"publisher":"MDPI AG","issue":"4","license":[{"start":{"date-parts":[[2018,3,22]],"date-time":"2018-03-22T00:00:00Z","timestamp":1521676800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>Malignant mesothelioma (MM) constitutes a very aggressive tumor that arises from the pleural or peritoneal cavities and is highly refractory to conventional therapies. Several key genetic alterations are associated with the development and progression of MM including mutations of the CDKN2A\/ARF, NF2, and BAP1 tumor-suppressor genes. Notably, activating oncogene mutations are very rare; thus, it is difficult to develop effective inhibitors to treat MM. The NF2 gene encodes merlin, a protein that regulates multiple cell-signaling cascades including the Hippo pathway. MMs also exhibit inactivation of Hippo pathway components including LATS1\/2, strongly suggesting that merlin-Hippo pathway dysregulation plays a key role in the development and progression of MM. Furthermore, Hippo pathway inactivation has been shown to result in constitutive activation of the YAP1\/TAZ transcriptional coactivators, thereby conferring malignant phenotypes to mesothelial cells. Critical YAP1\/TAZ target genes, including prooncogenic CCDN1 and CTGF, have also been shown to enhance the malignant phenotypes of MM cells. Together, these data indicate the Hippo pathway as a therapeutic target for the treatment of MM, and support the development of new strategies to effectively target the activation status of YAP1\/TAZ as a promising therapeutic modality for this formidable disease.<\/jats:p>","DOI":"10.3390\/cancers10040090","type":"journal-article","created":{"date-parts":[[2018,3,22]],"date-time":"2018-03-22T14:39:31Z","timestamp":1521729571000},"page":"90","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":45,"title":["Targeting the Hippo Pathway Is a New Potential Therapeutic Modality for Malignant Mesothelioma"],"prefix":"10.3390","volume":"10","author":[{"given":"Yoshitaka","family":"Sekido","sequence":"first","affiliation":[{"name":"Division of Molecular Oncology, Aichi Cancer Center Research Institute, 1-1 Kanokoden, Chikusa-ku, Nagoya 464-8681, Japan"},{"name":"Department of Cancer Genetics, Nagoya University Graduate School of Medicine, Nagoya 464-8681, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2018,3,22]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1591","DOI":"10.1056\/NEJMra050152","article-title":"Advances in malignant mesothelioma","volume":"353","author":"Robinson","year":"2005","journal-title":"N. Engl. J. Med."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"2081","DOI":"10.1200\/JCO.2008.19.8523","article-title":"Malignant pleural mesothelioma","volume":"27","author":"Tsao","year":"2009","journal-title":"J. Clin. Oncol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"3087","DOI":"10.1158\/1078-0432.CCR-15-1130","article-title":"HMGB1 and Its Hyperacetylated Isoform are Sensitive and Specific Serum Biomarkers to Detect Asbestos Exposure and to Identify Mesothelioma Patients","volume":"22","author":"Napolitano","year":"2016","journal-title":"Clin. Cancer Res."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"53751","DOI":"10.18632\/oncotarget.17910","article-title":"Biomarkers for early diagnosis of malignant mesothelioma: Do we need another moonshot?","volume":"8","author":"Lagniau","year":"2017","journal-title":"Oncotarget"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.5858\/133.8.1317","article-title":"Guidelines for pathologic diagnosis of malignant mesothelioma: A consensus statement from the International Mesothelioma Interest Group","volume":"133","author":"Husain","year":"2009","journal-title":"Arch. Pathol. Lab. Med."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"3354","DOI":"10.1200\/JCO.2017.73.8401","article-title":"Long-Term Survival Outcomes of Cancer-Directed Surgery for Malignant Pleural Mesothelioma: Propensity Score Matching Analysis","volume":"35","author":"Nelson","year":"2017","journal-title":"J. Clin. Oncol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1631","DOI":"10.1097\/JTO.0b013e31826915f1","article-title":"Initial analysis of the international association for the study of lung cancer mesothelioma database","volume":"7","author":"Rusch","year":"2012","journal-title":"J. Thorac. Oncol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1038\/ng.3520","article-title":"Comprehensive genomic analysis of malignant pleural mesothelioma identifies recurrent mutations, gene fusions and splicing alterations","volume":"48","author":"Bueno","year":"2016","journal-title":"Nat. Genet."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1016\/j.jtho.2017.04.002","article-title":"Epidemiology of Environmental Exposure and Malignant Mesothelioma","volume":"12","author":"Liu","year":"2017","journal-title":"J. Thorac. Oncol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1038\/ng.912","article-title":"Germline BAP1 mutations predispose to malignant mesothelioma","volume":"43","author":"Testa","year":"2011","journal-title":"Nat. Genet."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1007\/s00595-015-1275-3","article-title":"Current surgical strategies for malignant pleural mesothelioma","volume":"46","author":"Takuwa","year":"2016","journal-title":"Surg. Today"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"2636","DOI":"10.1200\/JCO.2003.11.136","article-title":"Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma","volume":"21","author":"Vogelzang","year":"2003","journal-title":"J. Clin. Oncol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s00280-011-1655-3","article-title":"Review on clinical trials of targeted treatments in malignant mesothelioma","volume":"68","author":"Jakobsen","year":"2011","journal-title":"Cancer Chemother. Pharmacol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1649","DOI":"10.1093\/annonc\/mdv101","article-title":"Searching for targets for the systemic therapy of mesothelioma","volume":"26","author":"Stahel","year":"2015","journal-title":"Ann. Oncol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.lungcan.2012.06.011","article-title":"Cediranib in patients with malignant mesothelioma: A phase II trial of the University of Chicago Phase II Consortium","volume":"78","author":"Campbell","year":"2012","journal-title":"Lung Cancer"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1097\/JTO.0b013e318248242c","article-title":"Phase II study of dasatinib in patients with previously treated malignant mesothelioma (cancer and leukemia group B 30601): A brief report","volume":"7","author":"Dudek","year":"2012","journal-title":"J. Thorac. Oncol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1097\/JTO.0b013e31828c2b26","article-title":"Phase 2 study of sorafenib in malignant mesothelioma previously treated with platinum-containing chemotherapy","volume":"8","author":"Papa","year":"2013","journal-title":"J. Thorac. Oncol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1950","DOI":"10.1097\/JTO.0b013e3182333df5","article-title":"Brief report: A phase II study of sunitinib in malignant pleural mesothelioma. the NCIC Clinical Trials Group","volume":"6","author":"Laurie","year":"2011","journal-title":"J. Thorac. Oncol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"3591","DOI":"10.1200\/JCO.2017.72.9012","article-title":"Nintedanib Plus Pemetrexed\/Cisplatin in Patients With Malignant Pleural Mesothelioma: Phase II Results From the Randomized, Placebo-Controlled LUME-Meso Trial","volume":"35","author":"Grosso","year":"2017","journal-title":"J. Clin. Oncol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.1016\/S0140-6736(15)01238-6","article-title":"Bevacizumab for newly diagnosed pleural mesothelioma in the Mesothelioma Avastin Cisplatin Pemetrexed Study (MAPS): A randomised, controlled, open-label, phase 3 trial","volume":"387","author":"Zalcman","year":"2016","journal-title":"Lancet"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1016\/S1470-2045(13)70381-4","article-title":"Tremelimumab for patients with chemotherapy-resistant advanced malignant mesothelioma: An open-label, single-arm, phase 2 trial","volume":"14","author":"Calabro","year":"2013","journal-title":"Lancet Oncol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1016\/S1470-2045(17)30446-1","article-title":"Tremelimumab as second-line or third-line treatment in relapsed malignant mesothelioma (DETERMINE): A multicentre, international, randomised, double-blind, placebo-controlled phase 2b trial","volume":"18","author":"Maio","year":"2017","journal-title":"Lancet Oncol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1016\/S1470-2045(17)30169-9","article-title":"Clinical safety and activity of pembrolizumab in patients with malignant pleural mesothelioma (KEYNOTE-028): Preliminary results from a non-randomised, open-label, phase 1b trial","volume":"18","author":"Alley","year":"2017","journal-title":"Lancet Oncol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"350","DOI":"10.21037\/tlcr.2017.06.06","article-title":"Targeting the epigenome in malignant pleural mesothelioma","volume":"6","author":"McLoughlin","year":"2017","journal-title":"Transl. Lung Cancer Res."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"2237","DOI":"10.1002\/(SICI)1097-0142(19970601)79:11<2237::AID-CNCR23>3.0.CO;2-W","article-title":"Dihydro-5-azacytidine in malignant mesothelioma. A phase II trial demonstrating activity accompanied by cardiac toxicity. Cancer and Leukemia Group B","volume":"79","author":"Yogelzang","year":"1997","journal-title":"Cancer"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1016\/S1470-2045(15)70056-2","article-title":"Vorinostat in patients with advanced malignant pleural mesothelioma who have progressed on previous chemotherapy (VANTAGE-014): A phase 3, double-blind, randomised, placebo-controlled trial","volume":"16","author":"Krug","year":"2015","journal-title":"Lancet Oncol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1038\/nm.3947","article-title":"Loss of BAP1 function leads to EZH2-dependent transformation","volume":"21","author":"LaFave","year":"2015","journal-title":"Nat. Med."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"4171","DOI":"10.1200\/JCO.2016.68.3672","article-title":"Mesothelin Immunotherapy for Cancer: Ready for Prime Time?","volume":"34","author":"Hassan","year":"2016","journal-title":"J. Clin. Oncol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1038\/bjc.2017.62","article-title":"First-in-human phase 1 of YS110, a monoclonal antibody directed against CD26 in advanced CD26-expressing cancers","volume":"116","author":"Angevin","year":"2017","journal-title":"Br. J. Cancer"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1001\/jamaoncol.2016.3049","article-title":"Arginine Deprivation With Pegylated Arginine Deiminase in Patients With Argininosuccinate Synthetase 1-Deficient Malignant Pleural Mesothelioma: A Randomized Clinical Trial","volume":"3","author":"Szlosarek","year":"2017","journal-title":"JAMA Oncol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1038\/nrc.2017.42","article-title":"Novel insights into mesothelioma biology and implications for therapy","volume":"17","author":"Yap","year":"2017","journal-title":"Nat. Rev. Cancer"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.lungcan.2017.03.005","article-title":"Targeting BAP1: A new paradigm for mesothelioma","volume":"109","author":"Schunselaar","year":"2017","journal-title":"Lung Cancer"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"e532","DOI":"10.1016\/S1470-2045(17)30459-X","article-title":"Radiotherapy for the treatment of malignant pleural mesothelioma","volume":"18","author":"Perrot","year":"2017","journal-title":"Lancet Oncol."},{"key":"ref_34","doi-asserted-by":"crossref","unstructured":"Kindler, H.L., Ismaila, N., Armato, S.G., Bueno, R., Hesdorffer, M., Jahan, T., Jones, C.M., Miettinen, M., Pass, H., and Rimner, A. (2018). Treatment of Malignant Pleural Mesothelioma: American Society of Clinical Oncology Clinical Practice Guideline. J. Clin. Oncol., JCO2017766394.","DOI":"10.1200\/JCO.2017.76.6394"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1038\/onc.2015.125","article-title":"Role of Merlin\/NF2 inactivation in tumor biology","volume":"35","author":"Petrilli","year":"2016","journal-title":"Oncogene"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1016\/j.devcel.2010.09.011","article-title":"The hippo signaling pathway in development and cancer","volume":"19","author":"Pan","year":"2010","journal-title":"Dev. Cell"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1016\/j.cell.2015.10.044","article-title":"Hippo Pathway in Organ Size Control, Tissue Homeostasis, and Cancer","volume":"163","author":"Yu","year":"2015","journal-title":"Cell"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"1614","DOI":"10.1242\/dev.102376","article-title":"The Hippo pathway effectors TAZ and YAP in development, homeostasis and disease","volume":"141","author":"Varelas","year":"2014","journal-title":"Development"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"2743","DOI":"10.1016\/j.febslet.2014.04.001","article-title":"Molecular insights into NF2\/Merlin tumor suppressor function","volume":"588","author":"Cooper","year":"2014","journal-title":"FEBS Lett."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1038\/cr.2015.69","article-title":"Angiomotin binding-induced activation of Merlin\/NF2 in the Hippo pathway","volume":"25","author":"Li","year":"2015","journal-title":"Cell Res."},{"key":"ref_41","first-page":"1227","article-title":"Neurofibromatosis type 2 (NF2) gene is somatically mutated in mesothelioma but not in lung cancer","volume":"55","author":"Sekido","year":"1995","journal-title":"Cancer Res."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"10854","DOI":"10.1073\/pnas.92.24.10854","article-title":"High frequency of inactivating mutations in the neurofibromatosis type 2 gene (NF2) in primary malignant mesotheliomas","volume":"92","author":"Bianchi","year":"1995","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1002\/(SICI)1098-2264(199903)24:3<238::AID-GCC9>3.0.CO;2-M","article-title":"Frequent mutations of NF2 and allelic loss from chromosome band 22q12 in malignant mesothelioma: Evidence for a two-hit mechanism of NF2 inactivation","volume":"24","author":"Cheng","year":"1999","journal-title":"Genes Chromosomes Cancer"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/j.lungcan.2008.08.014","article-title":"Functional inactivation of NF2\/merlin in human mesothelioma","volume":"64","author":"Thurneysen","year":"2009","journal-title":"Lung Cancer"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1038\/nature04856","article-title":"Tumorigenic transformation by CPI-17 through inhibition of a merlin phosphatase","volume":"442","author":"Jin","year":"2006","journal-title":"Nature"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1093\/hmg\/8.2.267","article-title":"Increased expression of the NF2 tumor suppressor gene product, merlin, impairs cell motility, adhesionand spreading","volume":"8","author":"Gutmann","year":"1999","journal-title":"Hum. Mol. Genet."},{"key":"ref_47","doi-asserted-by":"crossref","unstructured":"Zoch, A., Mayerl, S., Schulz, A., Greither, T., Frappart, L., Rubsam, J., Heuer, H., Giovannini, M., and Morrison, H. (2015). Merlin Isoforms 1 and 2 Both Act as Tumour Suppressors and Are Required for Optimal Sperm Maturation. PLoS ONE, 10.","DOI":"10.1371\/journal.pone.0129151"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1002\/gcc.20669","article-title":"CDKN2A, NF2, and JUN are dysregulated among other genes by miRNAs in malignant mesothelioma-A miRNA microarray analysis","volume":"48","author":"Guled","year":"2009","journal-title":"Genes Chromosomes Cancer"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"5960","DOI":"10.1038\/sj.onc.1209587","article-title":"Re-expression of the tumor suppressor NF2\/merlin inhibits invasiveness in mesothelioma cells and negatively regulates FAK","volume":"25","author":"Poulikakos","year":"2006","journal-title":"Oncogene"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"3799","DOI":"10.1038\/sj.onc.1206593","article-title":"Hemizygosity of Nf2 is associated with increased susceptibility to asbestos-induced peritoneal tumours","volume":"22","author":"Lecomte","year":"2003","journal-title":"Oncogene"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"8090","DOI":"10.1158\/0008-5472.CAN-05-2312","article-title":"A mouse model recapitulating molecular features of human mesothelioma","volume":"65","author":"Altomare","year":"2005","journal-title":"Cancer Res."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/j.ccr.2008.01.030","article-title":"A conditional mouse model for malignant mesothelioma","volume":"13","author":"Jongsma","year":"2008","journal-title":"Cancer Cell"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1016\/j.cell.2010.01.029","article-title":"Merlin\/NF2 suppresses tumorigenesis by inhibiting the E3 ubiquitin ligase CRL4(DCAF1) in the nucleus","volume":"140","author":"Li","year":"2010","journal-title":"Cell"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.ccr.2014.05.001","article-title":"Merlin\/NF2 loss-driven tumorigenesis linked to CRL4(DCAF1)-mediated inhibition of the hippo pathway kinases Lats1 and 2 in the nucleus","volume":"26","author":"Li","year":"2014","journal-title":"Cancer Cell"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"2950","DOI":"10.1016\/j.celrep.2016.02.075","article-title":"Merlin\/NF2-Lin28B-let-7 Is a Tumor-Suppressive Pathway that Is Cell-Density Dependent and Hippo Independent","volume":"14","author":"Hikasa","year":"2016","journal-title":"Cell Rep."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.1126\/science.1233009","article-title":"Genomic analysis of non-NF2 meningiomas reveals mutations in TRAF7, KLF4, AKT1, and SMO","volume":"339","author":"Clark","year":"2013","journal-title":"Science"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1038\/nrc3458","article-title":"The Hippo pathway and human cancer","volume":"13","author":"Harvey","year":"2013","journal-title":"Nat. Rev. Cancer"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"16084","DOI":"10.18632\/oncotarget.14306","article-title":"The Hippo signaling pathway provides novel anti-cancer drug targets","volume":"8","author":"Bae","year":"2017","journal-title":"Oncotarget"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.canlet.2017.03.001","article-title":"YAP and WWTR1: New targets for skin cancer treatment","volume":"396","author":"Andl","year":"2017","journal-title":"Cancer Lett."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.canlet.2018.01.062","article-title":"The Hippo pathway as a drug target in gastric cancer","volume":"420","author":"Qiao","year":"2018","journal-title":"Cancer Lett."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1158\/0008-5472.CAN-10-2164","article-title":"LATS2 is a tumor suppressor gene of malignant mesothelioma","volume":"71","author":"Murakami","year":"2011","journal-title":"Cancer Res."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"3191","DOI":"10.1158\/1078-0432.CCR-16-1971","article-title":"Co-occurring Mutations of Tumor Suppressor Genes, LATS2 and NF2, in Malignant Pleural Mesothelioma","volume":"23","author":"Tranchant","year":"2017","journal-title":"Clin. Cancer Res."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1097\/JTO.0000000000000493","article-title":"Hippo pathway gene mutations in malignant mesothelioma: Revealed by RNA and targeted exon sequencing","volume":"10","author":"Miyanaga","year":"2015","journal-title":"J. Thorac. Oncol."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1038\/onc.2013.528","article-title":"LIM-domain protein AJUBA suppresses malignant mesothelioma cell proliferation via Hippo signaling cascade","volume":"34","author":"Tanaka","year":"2015","journal-title":"Oncogene"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"2526","DOI":"10.1128\/MCB.00136-16","article-title":"AJUBA LIM Proteins Limit Hippo Activity in Proliferating Cells by Sequestering the Hippo Core Kinase Complex in the Cytosol","volume":"36","author":"Jagannathan","year":"2016","journal-title":"Mol. Cell. Biol."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.1002\/pros.23356","article-title":"Androgen receptor-regulated miRNA-193a-3p targets AJUBA to promote prostate cancer cell migration","volume":"77","author":"Jia","year":"2017","journal-title":"Prostate"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"2608","DOI":"10.18632\/oncotarget.1844","article-title":"YAP1 acts as oncogenic target of 11q22 amplification in multiple cancer subtypes","volume":"5","author":"Lorenzetto","year":"2014","journal-title":"Oncotarget"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"2139","DOI":"10.1093\/carcin\/bgn200","article-title":"YAP1 is involved in mesothelioma development and negatively regulated by Merlin through phosphorylation","volume":"29","author":"Yokoyama","year":"2008","journal-title":"Carcinogenesis"},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"5117","DOI":"10.1038\/onc.2012.5","article-title":"YAP induces malignant mesothelioma cell proliferation by upregulating transcription of cell cycle-promoting genes","volume":"31","author":"Mizuno","year":"2012","journal-title":"Oncogene"},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1084\/jem.20111653","article-title":"TGF-beta synergizes with defects in the Hippo pathway to stimulate human malignant mesothelioma growth","volume":"209","author":"Fujii","year":"2012","journal-title":"J. Exp. Med."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1093\/carcin\/bgw084","article-title":"Modeling mesothelioma utilizing human mesothelial cells reveals involvement of phospholipase-C beta 4 in YAP-active mesothelioma cell proliferation","volume":"37","author":"Kakiuchi","year":"2016","journal-title":"Carcinogenesis"},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1002\/path.4377","article-title":"Connective tissue growth factor and beta-catenin constitute an autocrine loop for activation in rat sarcomatoid mesothelioma","volume":"233","author":"Jiang","year":"2014","journal-title":"J. Pathol."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1016\/j.cell.2012.06.037","article-title":"Regulation of the Hippo-YAP pathway by G-protein-coupled receptor signaling","volume":"150","author":"Yu","year":"2012","journal-title":"Cell"},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1016\/j.ccr.2014.04.017","article-title":"Mutant Gq\/11 promote uveal melanoma tumorigenesis by activating YAP","volume":"25","author":"Yu","year":"2014","journal-title":"Cancer Cell"},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1016\/j.ccr.2014.04.016","article-title":"Hippo-independent activation of YAP by the GNAQ uveal melanoma oncogene through a trio-regulated rho GTPase signaling circuitry","volume":"25","author":"Feng","year":"2014","journal-title":"Cancer Cell"},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"4624","DOI":"10.18632\/oncotarget.6614","article-title":"Deep sequencing of uveal melanoma identifies a recurrent mutation in PLCB4","volume":"7","author":"Johansson","year":"2016","journal-title":"Oncotarget"},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"1410","DOI":"10.1126\/science.1194472","article-title":"Frequent mutation of BAP1 in metastasizing uveal melanomas","volume":"330","author":"Harbour","year":"2010","journal-title":"Science"},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1038\/ng.855","article-title":"The nuclear deubiquitinase BAP1 is commonly inactivated by somatic mutations and 3p21.1 losses in malignant pleural mesothelioma","volume":"43","author":"Bott","year":"2011","journal-title":"Nat. Genet."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1111\/j.1349-7006.2012.02223.x","article-title":"Frequent inactivation of BAP1 gene in epithelioid-type malignant mesothelioma","volume":"103","author":"Yoshikawa","year":"2012","journal-title":"Cancer Sci."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1016\/j.ccell.2017.07.003","article-title":"Integrative Analysis Identifies Four Molecular and Clinical Subsets in Uveal Melanoma","volume":"32","author":"Robertson","year":"2017","journal-title":"Cancer Cell"},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1038\/nrc3459","article-title":"BAP1 and cancer","volume":"13","author":"Carbone","year":"2013","journal-title":"Nat. Rev. Cancer"},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1038\/nature22798","article-title":"BAP1 regulates IP3R3-mediated Ca(2+) flux to mitochondria suppressing cell transformation","volume":"546","author":"Bononi","year":"2017","journal-title":"Nature"},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1016\/j.cell.2011.02.013","article-title":"Hallmarks of cancer: The next generation","volume":"144","author":"Hanahan","year":"2011","journal-title":"Cell"},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1093\/carcin\/bgt166","article-title":"Molecular pathogenesis of malignant mesothelioma","volume":"34","author":"Sekido","year":"2013","journal-title":"Carcinogenesis"},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.lungcan.2016.12.017","article-title":"Immunohistochemical detection of MTAP and BAP1 protein loss for mesothelioma diagnosis: Comparison with 9p21 FISH and BAP1 immunohistochemistry","volume":"104","author":"Hida","year":"2017","journal-title":"Lung Cancer"},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1016\/j.molonc.2016.06.005","article-title":"Low Merlin expression and high Survivin labeling index are indicators for poor prognosis in patients with malignant pleural mesothelioma","volume":"10","author":"Meerang","year":"2016","journal-title":"Mol. Oncol."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1038\/modpathol.2015.121","article-title":"The prognostic significance of BAP1, NF2, and CDKN2A in malignant peritoneal mesothelioma","volume":"29","author":"Singhi","year":"2016","journal-title":"Mod. Pathol."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"237ra268","DOI":"10.1126\/scitranslmed.3008639","article-title":"Merlin deficiency predicts FAK inhibitor sensitivity: A synthetic lethal relationship","volume":"6","author":"Shapiro","year":"2014","journal-title":"Sci. Transl. Med."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"5522","DOI":"10.1038\/onc.2017.147","article-title":"E-cadherin expression is correlated with focal adhesion kinase inhibitor resistance in Merlin-negative malignant mesothelioma cells","volume":"36","author":"Kato","year":"2017","journal-title":"Oncogene"},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"335","DOI":"10.21037\/tlcr.2017.06.02","article-title":"Drug development against the hippo pathway in mesothelioma","volume":"6","author":"Woodard","year":"2017","journal-title":"Transl. Lung Cancer Res."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"1300","DOI":"10.1101\/gad.192856.112","article-title":"Genetic and pharmacological disruption of the TEAD-YAP complex suppresses the oncogenic activity of YAP","volume":"26","author":"Huang","year":"2012","journal-title":"Genes Dev."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"7602","DOI":"10.1038\/s41598-017-07632-8","article-title":"Verteporfin inhibits growth of human glioma in vitro without light activation","volume":"7","author":"Brodowska","year":"2017","journal-title":"Sci. Rep."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"2663","DOI":"10.1111\/jcmm.13182","article-title":"Targeting YAP in malignant pleural mesothelioma","volume":"21","author":"Zhang","year":"2017","journal-title":"J. Cell Mol. Med."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1096\/fj.14-262980","article-title":"Targeting Hippo pathway by specific interruption of YAP-TEAD interaction using cyclic YAP-like peptides","volume":"29","author":"Zhou","year":"2015","journal-title":"FASEB J."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1016\/j.ccr.2014.01.010","article-title":"A peptide mimicking VGLL4 function acts as a YAP antagonist therapy against gastric cancer","volume":"25","author":"Jiao","year":"2014","journal-title":"Cancer Cell"},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1038\/cr.2014.10","article-title":"VGLL4 functions as a new tumor suppressor in lung cancer by negatively regulating the YAP-TEAD transcriptional complex","volume":"24","author":"Zhang","year":"2014","journal-title":"Cell Res."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"14058","DOI":"10.1038\/ncomms14058","article-title":"VGLL4 targets a TCF4-TEAD4 complex to coregulate Wnt and Hippo signalling in colorectal cancer","volume":"8","author":"Jiao","year":"2017","journal-title":"Nat. Commun."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1016\/j.ccell.2017.03.007","article-title":"TIAM1 Antagonizes TAZ\/YAP Both in the Destruction Complex in the Cytoplasm and in the Nucleus to Inhibit Invasion of Intestinal Epithelial Cells","volume":"31","author":"Diamantopoulou","year":"2017","journal-title":"Cancer Cell"},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.bbrc.2013.09.025","article-title":"Expression profile and function of Wnt signaling mechanisms in malignant mesothelioma cells","volume":"440","author":"Fox","year":"2013","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1016\/j.tcb.2015.11.004","article-title":"Control of YAP\/TAZ Activity by Metabolic and Nutrient-Sensing Pathways","volume":"26","author":"Santinon","year":"2016","journal-title":"Trends Cell Biol."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1038\/ncb3113","article-title":"AMPK modulates Hippo pathway activity to regulate energy homeostasis","volume":"17","author":"Wang","year":"2015","journal-title":"Nat. Cell Biol."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1038\/ncb3111","article-title":"Cellular energy stress induces AMPK-mediated regulation of YAP and the Hippo pathway","volume":"17","author":"Mo","year":"2015","journal-title":"Nat. Cell Biol."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1016\/j.celrep.2014.09.036","article-title":"Energy stress regulates Hippo-YAP signaling involving AMPK-mediated regulation of angiomotin-like 1 protein","volume":"9","author":"DeRan","year":"2014","journal-title":"Cell Rep."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1146\/annurev-med-062613-093128","article-title":"Metformin in cancer treatment and prevention","volume":"66","author":"Morales","year":"2015","journal-title":"Annu. Rev. Med."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1016\/j.lungcan.2016.07.020","article-title":"Metformin and survival of people with type 2 diabetes and pleural mesothelioma: A population-based retrospective cohort study","volume":"99","author":"Wu","year":"2016","journal-title":"Lung Cancer"},{"key":"ref_106","doi-asserted-by":"crossref","unstructured":"Shimazu, K., Tada, Y., Morinaga, T., Shingyoji, M., Sekine, I., Shimada, H., Hiroshima, K., Namiki, T., Tatsumi, K., and Tagawa, M. (2017). Metformin produces growth inhibitory effects in combination with nutlin-3a on malignant mesothelioma through a cross-talk between mTOR and p53 pathways. BMC Cancer, 17.","DOI":"10.1186\/s12885-017-3300-y"},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"1616","DOI":"10.1164\/ajrccm.157.5.9709020","article-title":"Lovastatin induces apoptosis in malignant mesothelioma cells","volume":"157","author":"Rubins","year":"1998","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1002\/ijc.21832","article-title":"Statins revert doxorubicin resistance via nitric oxide in malignant mesothelioma","volume":"119","author":"Riganti","year":"2006","journal-title":"Int. J. Cancer"},{"key":"ref_109","doi-asserted-by":"crossref","unstructured":"Robinson, C., Alfonso, H., Woo, S., Walsh, A., Olsen, N., Musk, A.W., Robinson, B.W., Nowak, A.K., and Lake, R.A. (2014). Statins do not alter the incidence of mesothelioma in asbestos exposed mice or humans. PLoS ONE, 9.","DOI":"10.1371\/journal.pone.0103025"},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1038\/ncb2936","article-title":"Metabolic control of YAP and TAZ by the mevalonate pathway","volume":"16","author":"Sorrentino","year":"2014","journal-title":"Nat. Cell Biol."},{"key":"ref_111","first-page":"E89","article-title":"Interplay of mevalonate and Hippo pathways regulates RHAMM transcription via YAP to modulate breast cancer cell motility","volume":"111","author":"Wang","year":"2014","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/j.canlet.2016.10.020","article-title":"Statin suppresses Hippo pathway-inactivated malignant mesothelioma cells and blocks the YAP\/CD44 growth stimulatory axis","volume":"385","author":"Tanaka","year":"2016","journal-title":"Cancer Lett."},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"4235","DOI":"10.1128\/MCB.01578-08","article-title":"Loss of the tumor suppressor gene NF2, encoding merlin, constitutively activates integrin-dependent mTORC1 signaling","volume":"29","author":"Okada","year":"2009","journal-title":"Mol. Cell. Biol."},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1126\/science.1226344","article-title":"Genome sequencing identifies a basis for everolimus sensitivity","volume":"338","author":"Iyer","year":"2012","journal-title":"Science"},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1097\/JTO.0000000000000360","article-title":"SWOG S0722: Phase II study of mTOR inhibitor everolimus (RAD001) in advanced malignant pleural mesothelioma (MPM)","volume":"10","author":"Ou","year":"2015","journal-title":"J. Thorac. Oncol."},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"2874","DOI":"10.1158\/1078-0432.CCR-15-2225","article-title":"Phase I Study of Apitolisib (GDC-0980), Dual Phosphatidylinositol-3-Kinase and Mammalian Target of Rapamycin Kinase Inhibitor, in Patients with Advanced Solid Tumors","volume":"22","author":"Dolly","year":"2016","journal-title":"Clin. Cancer Res."},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.1158\/1535-7163.MCT-16-0821","article-title":"Combined Inhibition of NEDD8-Activating Enzyme and mTOR Suppresses NF2 Loss-Driven Tumorigenesis","volume":"16","author":"Cooper","year":"2017","journal-title":"Mol. Cancer Ther."},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1002\/ijc.28972","article-title":"Deregulated expression of connective tissue growth factor (CTGF\/CCN2) is linked to poor outcome in human cancer","volume":"137","author":"Wells","year":"2015","journal-title":"Int. J. Cancer"},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1186\/s12931-018-0720-4","article-title":"Radiation-induced pulmonary gene expression changes are attenuated by the CTGF antibody Pamrevlumab","volume":"19","author":"Sternlicht","year":"2018","journal-title":"Respir. Res."},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"44551","DOI":"10.18632\/oncotarget.6082","article-title":"Connective tissue growth factor as a novel therapeutic target in high grade serous ovarian cancer","volume":"6","author":"Gloss","year":"2015","journal-title":"Oncotarget"},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"12325","DOI":"10.1073\/pnas.1300415110","article-title":"CTGF antagonism with mAb FG-3019 enhances chemotherapy response without increasing drug delivery in murine ductal pancreas cancer","volume":"110","author":"Neesse","year":"2013","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1101\/gad.173435.111","article-title":"Cell detachment activates the Hippo pathway via cytoskeleton reorganization to induce anoikis","volume":"26","author":"Zhao","year":"2012","journal-title":"Genes Dev."},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1016\/j.fertnstert.2016.09.005","article-title":"Mesothelial cells and peritoneal homeostasis","volume":"106","author":"Mutsaers","year":"2016","journal-title":"Fertil. Steril."},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1016\/j.canlet.2016.03.031","article-title":"G protein-coupled receptors as promising cancer targets","volume":"376","author":"Liu","year":"2016","journal-title":"Cancer Lett."},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1002\/cncr.30393","article-title":"A phase 2 study of the sphingosine-1-phosphate antibody sonepcizumab in patients with metastatic renal cell carcinoma","volume":"123","author":"Pal","year":"2017","journal-title":"Cancer"},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"1603","DOI":"10.1111\/j.1349-7006.2008.00848.x","article-title":"Lysophosphatidic acid stimulates the proliferation and motility of malignant pleural mesothelioma cells through lysophosphatidic acid receptors, LPA1 and LPA2","volume":"99","author":"Yamada","year":"2008","journal-title":"Cancer Sci."},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1038\/nrd4161","article-title":"The two faces of Hippo: Targeting the Hippo pathway for regenerative medicine and cancer treatment","volume":"13","author":"Johnson","year":"2014","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"1457","DOI":"10.1158\/1535-7163.MCT-13-0918","article-title":"Identification, mechanism of action, and antitumor activity of a small molecule inhibitor of Hippo, TGF-beta, and Wnt signaling pathways","volume":"13","author":"Basu","year":"2014","journal-title":"Mol. Cancer Ther."},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1016\/j.fob.2015.06.007","article-title":"Small molecules inhibiting the nuclear localization of YAP\/TAZ for chemotherapeutics and chemosensitizers against breast cancers","volume":"5","author":"Oku","year":"2015","journal-title":"FEBS Open Bio"},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"E71","DOI":"10.1073\/pnas.1517188113","article-title":"Dysregulated YAP1\/TAZ and TGF-beta signaling mediate hepatocarcinogenesis in Mob1a\/1b-deficient mice","volume":"113","author":"Nishio","year":"2016","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"1962","DOI":"10.1158\/1535-7163.MCT-07-0052","article-title":"Inhibition of c-Src expression and activation in malignant pleural mesothelioma tissues leads to apoptosis, cell cycle arrest, and decreased migration and invasion","volume":"6","author":"Tsao","year":"2007","journal-title":"Mol. Cancer Ther."},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"76577","DOI":"10.18632\/oncotarget.10428","article-title":"Dasatinib modulates sensitivity to pemetrexed in malignant pleural mesothelioma cell lines","volume":"7","author":"Monica","year":"2016","journal-title":"Oncotarget"},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1016\/j.jtho.2017.10.033","article-title":"Biomarker-Integrated Neoadjuvant Dasatinib Trial in Resectable Malignant Pleural Mesothelioma","volume":"13","author":"Tsao","year":"2018","journal-title":"J. Thorac. Oncol."},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"107666","DOI":"10.18632\/oncotarget.22587","article-title":"Antitumor effects of the antiparasitic agent ivermectin via inhibition of Yes-associated protein 1 expression in gastric cancer","volume":"8","author":"Nambara","year":"2017","journal-title":"Oncotarget"},{"key":"ref_135","doi-asserted-by":"crossref","unstructured":"Qi, Y., Yu, J., Han, W., Fan, X., Qian, H., Wei, H., Tsai, Y.H., Zhao, J., Zhang, W., and Liu, Q. (2016). A splicing isoform of TEAD4 attenuates the Hippo-YAP signalling to inhibit tumour proliferation. Nat. Commun., 7.","DOI":"10.1038\/ncomms11840"},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1007\/s00280-017-3401-y","article-title":"Synthetic lethality in malignant pleural mesothelioma with PARP1 inhibition","volume":"80","author":"Srinivasan","year":"2017","journal-title":"Cancer Chemother. Pharmacol."},{"key":"ref_137","doi-asserted-by":"crossref","unstructured":"McCambridge, A.J., Napolitano, A., Mansfield, A.S., Fennell, D.A., Sekido, Y., Nowak, A.K., Reungwetwattana, T., Mao, W., Pass, H.I., and Carbone, M. (2018). State of the Art: Advances in Malignant Pleural Mesothelioma in 2017. J. Thorac. Oncol.","DOI":"10.1016\/j.jtho.2018.02.021"}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/10\/4\/90\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T14:58:08Z","timestamp":1760194688000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/10\/4\/90"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,3,22]]},"references-count":137,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2018,4]]}},"alternative-id":["cancers10040090"],"URL":"https:\/\/doi.org\/10.3390\/cancers10040090","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,3,22]]}}}